Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
28 août 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
08 août 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
07 août 2024 07h40 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
07 août 2024 07h30 HE
|
Intra-Cellular Therapies Inc.
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA’s strong prescription uptake continues: Q2...
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
24 juil. 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
18 juin 2024 07h30 HE
|
Intra-Cellular Therapies Inc.
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint...
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
10 juin 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference
29 mai 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
23 mai 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
08 mai 2024 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...